Pulmonary eosinophilia associated to treatment with natalizumab

Natalizumab (Tysabri(®)) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who star...

ver descrição completa

Detalhes bibliográficos
Autores: Curto, Elena, Munteis-Olivas, Elvira, Balcells Vilarnau, Eva, 1967-, Domínguez Álvarez, Marisol
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2016
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/58490
Acesso em linha:http://hdl.handle.net/10230/58490
http://dx.doi.org/10.4103/1817-1737.185762
Access Level:Acceso aberto
Palavra-chave:Multiple sclerosis
Natalizumab
Pulmonary eosinophilia
id ES_8e25e8f0da5b63e99e10eafcebf2475b
oai_identifier_str oai:recercat.cat:10230/58490
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pulmonary eosinophilia associated to treatment with natalizumabCurto, ElenaMunteis-Olivas, ElviraBalcells Vilarnau, Eva, 1967-Domínguez Álvarez, MarisolMultiple sclerosisNatalizumabPulmonary eosinophiliaNatalizumab (Tysabri(®)) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who started treatment with natalizumab. She began to show mild asthmatic symptoms until she needed admission to the hospital due to respiratory insufficiency. Blood tests showed peripheral eosinophilia and the thoracic computed tomography scan demonstrated pulmonary infiltrates. The bronchoscopy with the bronchoalveolar lavage resulted in eosinophilic alveolitis. No evidence of bacterial, fungal and parasitic infection, connective tissue disease, or vasculitis were observed. After discontinuation of natalizumab, the patient improved without other treatments. As MS is a prevalent disease and the use of natalizumab is increasing, we consider important to point out that this drug can be associated with pulmonary eosinophilia, especially in patients with allergic rhinoconjunctivitis or asthma.Medknow Publications202320232016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/58490http://dx.doi.org/10.4103/1817-1737.185762reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAnnals of Thoracic Medicine. 2016 Jul-Sep;11(3):224-6© 2016 Annals of Thoracic Medicine. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.http://creativecommons.org/licenses/by-nc-sa/3.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/584902026-05-29T05:05:01Z
dc.title.none.fl_str_mv Pulmonary eosinophilia associated to treatment with natalizumab
title Pulmonary eosinophilia associated to treatment with natalizumab
spellingShingle Pulmonary eosinophilia associated to treatment with natalizumab
Curto, Elena
Multiple sclerosis
Natalizumab
Pulmonary eosinophilia
title_short Pulmonary eosinophilia associated to treatment with natalizumab
title_full Pulmonary eosinophilia associated to treatment with natalizumab
title_fullStr Pulmonary eosinophilia associated to treatment with natalizumab
title_full_unstemmed Pulmonary eosinophilia associated to treatment with natalizumab
title_sort Pulmonary eosinophilia associated to treatment with natalizumab
dc.creator.none.fl_str_mv Curto, Elena
Munteis-Olivas, Elvira
Balcells Vilarnau, Eva, 1967-
Domínguez Álvarez, Marisol
author Curto, Elena
author_facet Curto, Elena
Munteis-Olivas, Elvira
Balcells Vilarnau, Eva, 1967-
Domínguez Álvarez, Marisol
author_role author
author2 Munteis-Olivas, Elvira
Balcells Vilarnau, Eva, 1967-
Domínguez Álvarez, Marisol
author2_role author
author
author
dc.subject.none.fl_str_mv Multiple sclerosis
Natalizumab
Pulmonary eosinophilia
topic Multiple sclerosis
Natalizumab
Pulmonary eosinophilia
description Natalizumab (Tysabri(®)) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who started treatment with natalizumab. She began to show mild asthmatic symptoms until she needed admission to the hospital due to respiratory insufficiency. Blood tests showed peripheral eosinophilia and the thoracic computed tomography scan demonstrated pulmonary infiltrates. The bronchoscopy with the bronchoalveolar lavage resulted in eosinophilic alveolitis. No evidence of bacterial, fungal and parasitic infection, connective tissue disease, or vasculitis were observed. After discontinuation of natalizumab, the patient improved without other treatments. As MS is a prevalent disease and the use of natalizumab is increasing, we consider important to point out that this drug can be associated with pulmonary eosinophilia, especially in patients with allergic rhinoconjunctivitis or asthma.
publishDate 2016
dc.date.none.fl_str_mv 2016
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/58490
http://dx.doi.org/10.4103/1817-1737.185762
url http://hdl.handle.net/10230/58490
http://dx.doi.org/10.4103/1817-1737.185762
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Annals of Thoracic Medicine. 2016 Jul-Sep;11(3):224-6
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Medknow Publications
publisher.none.fl_str_mv Medknow Publications
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413104958308352
score 15,812429

Registros relacionados